Prestige BioPharma Limited

KSE:950210.KS

18670 (KRW) • At close July 4, 2025
Overview | Financials

Numbers are in millions (except for per share data and ratios) KRW.

2024 Q32024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q3
Revenue 3,339.9453,114.812,221.648-137.09643.028119.89467.323161.05600000000572.2920000
Cost of Revenue 13,140.51718,704.12501,217.8684,478.7923,841.7923,414.9283,415.6473,263.9923,146.9311,800.186228.95955.456964.0460530.44300005.488
Gross Profit -9,682.038-15,589.3152,221.648-1,354.958-3,835.764-3,721.899-3,347.493-3,254.591-3,263.992-3,146.931-1,800.186-1,181.812-955.456-964.046-782.583-530.443572.2920000
Gross Profit Ratio -2.899-5.00519.884-5.965-31.043-49.723-20.2080000000010000
Reseach & Development Expenses 6,208.73905,137.08607,762.91911,906.2338,137.2611,159.02313,29211,070.1635,203.462333.769,401.1925,388.6112,456.7305,249.614000886.794
General & Administrative Expenses 18,686.09424,449.6317,724.778167.99117,381.63119,060.44417,242.858399.7119,726.56217,030.18112,358.679724.56512,968.0098,797.9785,307.721455.2199,152.3292,900.6222,490.828450.3321,104.683
Selling & Marketing Expenses 00012,694.298-12,121.808-15,665.1560000018,587.4310007,517.365224.509003,808.104286.224
SG&A 18,686.09424,449.6317,724.778-23,965.5895,259.8233,395.2885,719.509-9,089.7532,451.42917,030.18112,358.67930,819.29512,968.0098,797.9785,307.7213,452.3449,152.3292,900.6222,490.8287,042.2571,616.744
Other Expenses 00-0.00133,572.831316.96600.00118,682.84-1,212.317-14,052.54470,516.6615,670.177-72,559.935-4,829.7090-3,845.683-4,800.8163,091.3691,473.031-1,127.151,236.129
Operating Expenses 6,208.73924,449.6317,968.9958,422.55413,022.74215,301.52113,856.76920,885.71219,726.56220,122.9510,586.02631,249.35312,968.0097,931.3714,533.7163,452.3449,724.6212,841.7522,417.7093,017.2082,493.174
Operating Income -15,346.149-21,334.82-15,503.129-9,744.332-16,743.008-18,941.069-17,175.536-20,885.712-19,726.562-17,030.181-12,358.679-31,249.354-12,968.009-8,797.978-5,307.721-3,972.215-9,152.329-2,900.622-2,490.828-3,017.208-2,493.175
Operating Income Ratio -4.595-6.849-6.97871.08-26.038-157.982-255.121-129.6800000000-15.9920000
Total Other Income Expenses Net 61,541.528-263.6324,925.001-3,154.3473,591.2687,348.346283.0875,681.442-1,382.163-2,401.93466,202.454-69,922.365-72,363.403-4,837.796-4,862.9416,618.796-1,024.783,030.1452,090.156-4,013.226-155.569
Income Before Tax 46,195.379-21,598.452-10,645.066-12,898.679-13,151.74-11,592.723-16,892.449-15,204.27-21,108.725-19,432.11553,843.775-101,171.719-85,331.412-13,635.774-10,170.6622,646.581-10,177.109129.523-400.672-7,030.434-2,648.744
Income Before Tax Ratio 13.831-6.934-4.79294.089-20.453-96.692-250.916-94.40300000000-17.7830000
Income Tax Expense -1.478-167.268148.465157.145145.26-33.494139.756128.841411.6279.207215.938138.07399.585260.561-782.583-0.14928.5225.768-0.0470.762-154.995
Net Income 50,462.172-13,185.845-5,784.919-9,285.173-1,437.872-12,971.581-9,122.322-8,806.926-14,353.368-18,278.44259,277.404-101,309.789-85,730.996-13,896.335-10,187.0992,646.73-10,205.632119.943-400.373-7,031.196-2,648.744
Net Income Ratio 15.109-4.233-2.60467.73-2.236-108.192-135.501-54.68200000000-17.8330000
EPS 838.4-223.2-95.2-154.51-23.8-216.79-152-146.55-238.84-304.8987.4-1,684.69-1,427.2-231.8-169.2444.04-2102.4-9.6-157.27-64
EPS Diluted 838.4-223.2-95.2-154.51-23.8-215.8-152-146.55-238.4-304.8987.4-1,684.69-1,427.2-231.8-16944.04-2102.4-9.6-157.27-64
EBITDA -15,346.149-21,334.82-15,503.135,753.39-16,743.008-18,941.069-15,055.95947,542.291-19,726.562-17,030.18153,984.71-183,363.738-12,968.009-8,797.978-5,307.7213,105.467-9,152.329-2,900.622-2,490.828-2,465.15-2,438.183
EBITDA Ratio -4.595-6.849-6.978-41.968-26.038-157.982-223.638295.19100000000-15.9920000